The Journal of Immunology, Vol 155, Issue 11 5089-5094, Copyright © 1995 by American Association of Immunologists

ARTICLES

CTL in mice immunized with human mucin 1 are MHC-restricted

V Apostolopoulos, BE Loveland, GA Pietersz and IF McKenzie
Austin Research Institute, Heidelberg, Victoria, Australia.

CTLs that recognize tumor Ags have been described in mice and humans, particularly for melanoma. These CTLs are CD8+, which is MHC- restricted. In contrast, in human carcinomas of the breast, pancreas, or ovary, and in multiple myeloma, CD8+ CTLs have been described that lyse targets expressing human MUC1 in a non-MHC-restricted manner. On the basis of these observations, we immunized mice with conjugates of mannan-human fusion protein, human mucin 1 (MUC1), which produced CD8+ CTLs. In contrast to the human anti-MUC1 CTLs found in cancer patients, the murine anti-MUC1 CTLs were clearly MHC-restricted, e.g., in inbred mice of the H-2-b, d, k, s, or z haplotypes; the H-2 restriction was also confirmed in H-2 congenic strains. Tests of H-2 recombinant strains demonstrated that MUC1 peptides were able to associate with D or K class I molecules of the b, d, or k haplotypes. Mice lacking MHC- class I molecules made weak CTL responses that were H-2Db-restricted, and in the class I H-2Kbm1 mutant strain, CTL restriction was also shown. Finally, cold target inhibition studies demonstrated that Kb and Db are recognized similarly, but Kk is less well recognized. Thus, anti- MUC1 CTLs induced by immunization of mice are different from those obtained from patients. The immunization of cancer patients with MUC1 peptides is now undergoing clinical trials and it will be of interest to observe whether the CTLs induced are HLA-restricted, not restricted, or whether both types of CTLs are produced.

This article has been cited by other articles:

				G. Curigliano, G. Spitaleri, E. Pietri, M. Rescigno, F. de Braud, A. Cardillo, E. Munzone, A. Rocca, G. Bonizzi, V. Brichard, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann. Onc., May 1, 2006; 17(5): 750 - 762. [Abstract] [Full Text] [PDF]

				K. Y. Tsang, C. Palena, J. Yokokawa, P. M. Arlen, J. L. Gulley, G. P. Mazzara, L. Gritz, A. Gomez Yafal, S. Ogueta, P. Greenhalgh, et al. Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules Clin. Cancer Res., February 15, 2005; 11(4): 1597 - 1607. [Abstract] [Full Text] [PDF]

				P. Monti, B. E. Leone, A. Zerbi, G. Balzano, S. Cainarca, V. Sordi, M. Pontillo, A. Mercalli, V. Di Carlo, P. Allavena, et al. Tumor-Derived MUC1 Mucins Interact with Differentiating Monocytes and Induce IL-10highIL-12low Regulatory Dendritic Cell J. Immunol., June 15, 2004; 172(12): 7341 - 7349. [Abstract] [Full Text] [PDF]

				K.-Y. Tsang, C. Palena, J. Gulley, P. Arlen, and J. Schlom A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1 Clin. Cancer Res., March 15, 2004; 10(6): 2139 - 2149. [Abstract] [Full Text] [PDF]

				S. Brandlein, T. Pohle, N. Ruoff, E. Wozniak, H.-K. Muller-Hermelink, and H. P. Vollmers Natural IgM Antibodies and Immunosurveillance Mechanisms against Epithelial Cancer Cells in Humans Cancer Res., November 15, 2003; 63(22): 7995 - 8005. [Abstract] [Full Text] [PDF]

				B. K. Ko, K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides Clinical Studies of Vaccines Targeting Breast Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3222 - 3234. [Abstract] [Full Text] [PDF]

				E. M. Hiltbold, A. M. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells J. Immunol., October 1, 2000; 165(7): 3730 - 3741. [Abstract] [Full Text] [PDF]

				F. Hensel, R. Hermann, C. Schubert, N. Abe, K. Schmidt, A. Franke, A. Shevchenko, M. Mann, H. K. Muller-Hermelink, and H. P. Vollmers Characterization of Glycosylphosphatidylinositol-linked Molecule CD55/Decay-accelerating Factor as the Receptor for Antibody SC-1-induced Apoptosis Cancer Res., October 1, 1999; 59(20): 5299 - 5306. [Abstract] [Full Text] [PDF]

				V. Apostolopoulos, G. Chelvanayagam, P.-X. Xing, and I. F. C. McKenzie Anti-MUC1 Antibodies React Directly with MUC1 Peptides Presented by Class I H2 and HLA Molecules J. Immunol., July 15, 1998; 161(2): 767 - 775. [Abstract] [Full Text] [PDF]

				K. Engelmann, S. E. Baldus, and F.-G. Hanisch Identification and Topology of Variant Sequences within Individual Repeat Domains of the Human Epithelial Tumor Mucin MUC1 J. Biol. Chem., July 20, 2001; 276(30): 27764 - 27769. [Abstract] [Full Text] [PDF]